• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The study of bladder-preserving therapy with combined proton irradiation and intraarterial infution of anti-tumor agents in locally advanced bladder carcinoma.

Research Project

Project/Area Number 02670698
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field Urology
Research InstitutionTSUKUBA University

Principal Investigator

OHTANI Mikinobu  Clinical Medicine. Analogy. Assistant Professor, 臨床医学系, 講師 (80133081)

Project Period (FY) 1990 – 1992
Project Status Completed (Fiscal Year 1992)
Budget Amount *help
¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 1992: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1991: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1990: ¥500,000 (Direct Cost: ¥500,000)
KeywordsBladder Carcinoma / Intraarterial Infusion / Proton / Radiotherapy / Bladder Preservation / 膀胱保存
Research Abstract

Between August 1990 and December 1992, 21 patients with locally advanced (T2, 3 N0 M0) bladder carcinoma were treated with intraarterial infusion of anti-chemotheraputic agents and radiotherapy to preserve the bladder. Cisplatin (50mg/kg) and methotrexate (30 mg/kg) were administered via bilateral internal iliac artery infusion every 3 weeks (in total 3 times). Concurrently small pelvic field irradiation was performed with X -rays (41.4Gy), then if complete responce was achieved, proton beam irradiation (33Gy) to the original tumor site was followed.
A complete responce (CR) was seen in 19 patients (90.5%) and the other 2 patients were regarded as partial rsponders. Three of 19 complete responders underwent total cystectomy because they could not comfirm CR before cystecomy. Then, sixteen of the 19 complete responders and one of the 2 partial responders were preserved their bladders. Two of them were died of other diseases. Two patients in bladder-preserved group had recurrent tumors in their bladders. One was underwent total cystectomy and the other was controlled transurethral coagulation. The bladder function was preserved in thirteen patients and they have survived for a mean of 13.5 months (range 3-27) after the therapy without no evidence of disease. No severe side effects were observed in all patients.
From these preliminary results it is concluded that this therapy is viable regimen and could be considered as a means of preserving the bladder in patients with locally advanced bladder carcinoma.

Report

(4 results)
  • 1992 Annual Research Report   Final Research Report Summary
  • 1991 Annual Research Report
  • 1990 Annual Research Report
  • Research Products

    (7 results)

All Other

All Publications (7 results)

  • [Publications] 宮永 直人,大谷 幹伸ほか: "浸潤性膀胱癌に対する下殿動脈動注と放射線照射併用" 日本泌尿器科学会雑誌. 82. 1583-1587 (1991)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1992 Final Research Report Summary
  • [Publications] 大谷 幹伸ほか: "N-Butyl-N(4-hydroxybutyl)nihosemine によるマウス膀胱癌の進展に対する陽子線照射の効果" 日本泌尿器科学会雑誌. 82. 821-825 (1991)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1992 Final Research Report Summary
  • [Publications] 大谷 幹伸ほか: "再発性尿路上皮癌の治療" 泌尿器外科. 5. 469-472 (1992)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1992 Final Research Report Summary
  • [Publications] 大谷 幹伸: "局所浸潤性膀胱癌に対する動注と放射線照射の併用による、膀胱保存療法の検討" 第57回日本泌尿器科学会東部総合予稿集. 49- (1992)

    • Related Report
      1992 Annual Research Report
  • [Publications] 宮永直人: "浸潤性膀胱癌に対する下殿動脈動注と放射線照射の併用" 日本泌尿器科学会雑誌. 82. 1583-1587 (1991)

    • Related Report
      1991 Annual Research Report
  • [Publications] 大谷幹伸: "NーButylーNー(4ーHydroxy Butyl)nitrosamineによるマウス膀胱癌の進展に対する陽子線照射の効果" 日本泌尿器科学会雑誌. 82. 821-825 (1991)

    • Related Report
      1991 Annual Research Report
  • [Publications] 大谷 幹伸、宮永 直人ほか.: "NーButylーNー(4ーHydroxybutyl)nitrosamineによるマウス膀胱癌の進展に対する陽子線照射の効果" 日本泌尿器科学会雑誌. 82. (1981)

    • Related Report
      1990 Annual Research Report

URL: 

Published: 1990-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi